183 related articles for article (PubMed ID: 18413372)
1. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P
J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372
[TBL] [Abstract][Full Text] [Related]
2. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
3. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
Stirling D; Evans DG; Pichert G; Shenton A; Kirk EN; Rimmer S; Steel CM; Lawson S; Busby-Earle RM; Walker J; Lalloo FI; Eccles DM; Lucassen AM; Porteous ME
J Clin Oncol; 2005 Aug; 23(24):5588-96. PubMed ID: 16110018
[TBL] [Abstract][Full Text] [Related]
4. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
van der Velde NM; Mourits MJ; Arts HJ; de Vries J; Leegte BK; Dijkhuis G; Oosterwijk JC; de Bock GH
Int J Cancer; 2009 Feb; 124(4):919-23. PubMed ID: 19035463
[TBL] [Abstract][Full Text] [Related]
5. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
Hermsen BB; Olivier RI; Verheijen RH; van Beurden M; de Hullu JA; Massuger LF; Burger CW; Brekelmans CT; Mourits MJ; de Bock GH; Gaarenstroom KN; van Boven HH; Mooij TM; Rookus MA
Br J Cancer; 2007 May; 96(9):1335-42. PubMed ID: 17426707
[TBL] [Abstract][Full Text] [Related]
6. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.
Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R
Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167
[TBL] [Abstract][Full Text] [Related]
7. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
8. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.
Gaarenstroom KN; van der Hiel B; Tollenaar RA; Vink GR; Jansen FW; van Asperen CJ; Kenter GG
Int J Gynecol Cancer; 2006; 16 Suppl 1():54-9. PubMed ID: 16515568
[TBL] [Abstract][Full Text] [Related]
10. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.
Woodward ER; Sleightholme HV; Considine AM; Williamson S; McHugo JM; Cruger DG
BJOG; 2007 Dec; 114(12):1500-9. PubMed ID: 17903229
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
Bjørge T; Lie AK; Hovig E; Gislefoss RE; Hansen S; Jellum E; Langseth H; Nustad K; Tropé CG; Dørum A
Br J Cancer; 2004 Nov; 91(10):1829-34. PubMed ID: 15477862
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
Cortesi L; De Matteis E; Toss A; Marchi I; Medici V; Contu G; Xholli A; Grandi G; Cagnacci A; Federico M
Oncology; 2017; 93(6):377-386. PubMed ID: 28848147
[TBL] [Abstract][Full Text] [Related]
13. Improved survival in BRCA2 carriers with ovarian cancer.
Pal T; Permuth-Wey J; Kapoor R; Cantor A; Sutphen R
Fam Cancer; 2007; 6(1):113-9. PubMed ID: 17160431
[TBL] [Abstract][Full Text] [Related]
14. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
15. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
16. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
17. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
18. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
Vos JR; de Bock GH; Teixeira N; van der Kolk DM; Jansen L; Mourits MJ; Oosterwijk JC
Eur J Cancer; 2013 Jun; 49(9):2101-6. PubMed ID: 23490645
[TBL] [Abstract][Full Text] [Related]
19. Early detection of breast and ovarian cancer in families with BRCA mutations.
Vasen HF; Tesfay E; Boonstra H; Mourits MJ; Rutgers E; Verheyen R; Oosterwijk J; Beex L
Eur J Cancer; 2005 Mar; 41(4):549-54. PubMed ID: 15737559
[TBL] [Abstract][Full Text] [Related]
20. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
